Outcomes after thrombolysis in AIS according to prior statin use

Background: The impact of prior statin use on outcomes after thrombolysis is unclear. We evaluated outcomes of patients treated by IV, intra-arterial (IA) thrombolysis, or combined therapy, according to prior statin use. Methods: We analyzed data from a patient registry (606 patients) and conducted a systematic review. Results: We identified 11 previous studies (6,438 patients) that evaluated the effect of statin use on outcomes after IV thrombolysis (8 studies), IA thrombolysis (2 studies), or a single/combined approach (1 study). In our registry and in most of the retrieved studies, statin users had more risk factors and concomitant antiplatelet treatment than nonstatin users. Regardless of treatment strategy, prior statin use was not associated with favorable outcome (adjusted odds ratio [OR] 1.36; 95 confidence interval [CI] 0.86–2.16), symptomatic intracranial hemorrhage (sICH) (OR 0.57; 95% CI 0.22–1.49), or recanalization (OR 1.87; 95% CI 0.69–5.03). In meta-analysis, prior statin use was not associated with favorable outcome (crude OR 0.99; 95% CI 0.88–1.12), but was associated with an increased risk of sICH (crude OR 1.55; 95% CI 1.23–1.95). However, when the available multivariable associations were combined (5 studies), the effect of prior statin use on risk of sICH was not significant (OR 1.31; 95% CI 0.97–1.76). Conclusions: These results suggest no beneficial or detrimental effect of prior statin use in acute stroke patients treated by IV thrombolysis, IA thrombolysis, or combined therapy, although the numbers of patients treated by IA thrombolysis or combined therapy are too small to exclude an effect.

[1]  M. Hennerici,et al.  Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. , 2011, Archives of neurology.

[2]  G. Moretto,et al.  Does statin in the acute phase of ischemic stroke improve outcome after intravenous thrombolysis? A retrospective study , 2011, Journal of the Neurological Sciences.

[3]  R. Bordet,et al.  IV thrombolysis and statins , 2011, Neurology.

[4]  J. Serfaty,et al.  Outcomes of Mechanical Endovascular Therapy for Acute Ischemic Stroke: A Clinical Registry Study and Systematic Review , 2011, Stroke.

[5]  R. Delgado-Mederos,et al.  Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case–control study and a meta-analysis , 2011, Journal of Neurology.

[6]  E. Sagui,et al.  Expérience de la thrombolyse intraveineuse des infarctus cérébraux à l'hôpital d'instruction des armées Sainte-Anne de Toulon de septembre 2003 à juin 2009 , 2010 .

[7]  S. Lakhan,et al.  Statins and clinical outcome of acute ischemic stroke: a systematic review , 2010, International archives of medicine.

[8]  A. Arboix,et al.  Pretreatment with statins improves early outcome in patients with first-ever ischaemic stroke: a pleiotropic effect of statins or a beneficial effect of hypercholesterolemia? , 2010, BMC neurology.

[9]  譲二 中川原,et al.  rt-PA静注療法施行症例におけるスタチンの頭蓋内出血および転帰におよぼす影響 : Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) rt-PA Registry , 2010 .

[10]  J. De Keyser,et al.  Statin Use and Functional Outcome after Tissue Plasminogen Activator Treatment in Acute Ischaemic Stroke , 2010, Cerebrovascular Diseases.

[11]  J. Grapperon,et al.  [Intravenous thrombolysis with rt-PA in stroke: experience of the French military hospital of Toulon from September 2003 to June 2009]. , 2010, Revue neurologique.

[12]  K. Kario,et al.  [Effects of statin use on intracranial hemorrhage and clinical outcome after intravenous rt-PA for acute ischemic stroke: SAMURAI rt-PA registry]. , 2010, Rinsho shinkeigaku = Clinical neurology.

[13]  M. Hennerici,et al.  Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial , 2009, Stroke.

[14]  J. Serfaty,et al.  Comparison of intravenous alteplase with a combined intravenous–endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study , 2009, The Lancet Neurology.

[15]  G. Duckwiler,et al.  Impact of Hyperlipidemia and Statins on Ischemic Stroke Outcomes after Intra-Arterial Fibrinolysis and Percutaneous Mechanical Embolectomy , 2009, Cerebrovascular Diseases.

[16]  J. Olivot,et al.  Outcomes of Intravenous Recombinant Tissue Plasminogen Activator Therapy According to Gender: A Clinical Registry Study and Systematic Review , 2009, Stroke.

[17]  G. Schroth,et al.  Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. , 2009, Stroke.

[18]  P. Amarenco,et al.  Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention , 2009, The Lancet Neurology.

[19]  M. Vermeulen,et al.  HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDY , 2009, Neurology.

[20]  L. Mascitelli,et al.  HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDY , 2009, Neurology.

[21]  Q. Shah,et al.  Premorbid Use of Statins Is Associated with Higher Recanalization Rates in Patients with Acute Ischemic Stroke Undergoing Endovascular Treatment , 2009, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[22]  G. Luijckx,et al.  Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke , 2008, Journal of Neurology.

[23]  C. Molina,et al.  Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial , 2007, European journal of neurology.

[24]  J. Montaner.  Cholesterol measured before stroke thrombolysis is not associated with tissue plasminogen activator-related hemorrhagic transformation. , 2008, Stroke.

[25]  M. A. Moro,et al.  Statin treatment withdrawal in ischemic stroke , 2007, Neurology.

[26]  N. Salamon,et al.  Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis , 2007, Neurology.

[27]  C. Molina,et al.  Prior Statin Use May Be Associated With Improved Stroke Outcome After Tissue Plasminogen Activator , 2007, Stroke.

[28]  F. Dubas.  Pathologie des petites arteres et hémorragies cérébrales , 2003 .

[29]  E. Tremoli,et al.  Treatment With Statins After Induction of Focal Ischemia in Rats Reduces the Extent of Brain Damage , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[30]  K. Hirata,et al.  HMG-CoA Reductase Inhibitor Has Protective Effects Against Stroke Events in Stroke-Prone Spontaneously Hypertensive Rats , 2003, Stroke.

[31]  F. Dubas.  [Small vessel pathology and cerebral hemorrhage]. , 2003, Journal of neuroradiology. Journal de neuroradiologie.

[32]  Theo Stijnen,et al.  Advanced methods in meta‐analysis: multivariate approach and meta‐regression , 2002, Statistics in medicine.

[33]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[34]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[35]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.